| 망막정맥폐쇄에 의한 황반부종 환자에서 유리체강 내 베바시주맙 주입술과 트리암시놀론 주입술의 치료 효과 비교 |
|
현상훈, 이대영 |
|
Department of Ophthalmology, Gachon University Gil Medical Center, Incheon, Korea |
| Comparison of Bevacizumab and Triamcinolone Acetonide for the Treatment of Retinal Vein Occlusion |
|
Sang Hun Hyun, Dae Young Lee |
|
|
| Abstract |
Purpose
To evaluate the treatment effect of intravitreal bevacizumab injections in patients with retinal vein occlusion, and to compare the clinical outcomes of bevacizumab treated patients with those of Triamcinolone Acetonide (TA) treated patients. Methods: A retrospective chart review will be conducted on patients who are identified with CRVO or BRVO, and are treated by intravitreal bevacizumab or TA injection. Results: There were 47 patients diagnosed with BRVO. Seventeen eyes were treated with intravitreal bevacizumab injections and 30 eyes with intravitreal TA injections. In both group, there were improvements in visual acuity at 1-, 2-, and 3-month follow-up, and declination of central macular thickness at 1-month follow-up (p＜0.05). Twenty two patients were diagnosed with CRVO, and treated with bevacizumab (8 patients) and TA (14 patients). In both two groups, mean visual acuity was improved in all follow-up periods (p＜0.05). No significant differences of the treatment effect between bevacizumab and TA were found in this study. Conclusions: The visual benefits of intravitreal bevacizumab for macular edema are almost equvalent to those of intravitreal TA injections. On the basis of the results of this study, intravitreal injection of bevacizumab may be an alternative or even first-line treatment for RVO patients with the risk of steroid complications. (Korean J Optom Vis Sci 2012;11(1):96-106) |
| Key Words:
Bevacizumab, Retinal vein occlusion, Macular edema, Intravitreal triamcinolone acetonide injection |
|
PDF Links
Download Citation
